Erythropoietic Protoporphyria (EPP) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Erythropoietic Protoporphyria Emerging Therapy and TPP Insights

Thelansis’s “Erythropoietic Protoporphyria (EPP) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Erythropoietic Protoporphyria (EPP) Overview

Erythropoietic protoporphyria (EPP) is a rare inherited disorder of heme biosynthesis caused by partial ferrochelatase (FECH) deficiency, leading to accumulation of protoporphyrin in erythrocytes and tissues and triggering severe burning pain within minutes of visible-light exposure. For decades, management relied largely on strict light avoidance and protective measures. Afamelanotide, the established pharmacologic treatment in approved settings, activates the melanocortin-1 receptor to increase eumelanin and extend pain-free light exposure, but does not correct the underlying metabolic defect. The pipeline is now becoming more competitive. Oral dersimelagon, another MC1R agonist, met its Phase 3 INSPIRE primary endpoint in adults and adolescents with EPP/XLP and demonstrated improvements across several secondary measures, although it remains investigational. Meanwhile, bitopertin targets the heme pathway upstream to reduce protoporphyrin production; after an FDA Complete Response Letter, its ongoing Phase 3 APOLLO study is intended to provide additional evidence for potential approval. For stakeholders, EPP illustrates the shift from managing phototoxicity toward therapies targeting the metabolic source of disease.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)